Reaktion #660031

Reaktionsgleichung

2-[(3-bromophenyl)(1-methylpiperidin-4-yloxy)methyl]benzothiazole

RuPhos

potassium 3-trifluoroboratopropionate tert-butyl ester

potassium carbonate

→

3-{3-[benzothiazol-2-yl(1-methylpiperidin-4-yloxy)methyl]phenyl}propionic acid tert-butyl ester

Lösungsmittel

toluene

water

Reaktionsbedingungen

Aufarbeitung

1. 1
   SonstigeThe tube is evacuated
2. 2
   workup.ADDITIONfilled with argon
3. 3
   Sonstigesealed
4. 4
   workup.ADDITIONthe mixture is diluted with ethyl acetate and water
5. 5
   Extraktionthe aqueous phase is extracted with ethyl acetate
6. 6
   TrocknenThe pooled organic extracts are dried over magnesium sulfate
7. 7
   Einengenconcentrated under reduced pressure
8. 8
   SonstigeThe residue is purified by chromatography (gradient dichloromethane/methanol from 100/0 to 95/5)

Vorschrift

A screw-cap tube is charged with 2-[(3-bromophenyl)(1-methylpiperidin-4-yloxy)methyl]benzothiazole (208 mg), palladium(II) acetate (3 mg), RuPhos® (12 mg), potassium 3-trifluoroboratopropionate tert-butyl ester (118 mg), potassium carbonate (207 mg), water (2.5 mL) and toluene (2.5 mL). The tube is evacuated, filled with argon and sealed. After stirring at 120° C. overnight, the mixture is diluted with ethyl acetate and water and the aqueous phase is extracted with ethyl acetate. The pooled organic extracts are dried over magnesium sulfate and concentrated under reduced pressure. The residue is purified by chromatography (gradient dichloromethane/methanol from 100/0 to 95/5) to afford 3-{3-[benzothiazol-2-yl(1-methylpiperidin-4-yloxy)methyl]phenyl}propionic acid tert-butyl ester.

Quelle